Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04969861 · ClinicalTrials.gov registry record · Phase 2
BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)
A Phase 2 study, sponsored by Nektar Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT04969861 is a Phase 2 study that was terminated before completion, run by Nektar Therapeutics. The registered enrollment target is 1 participants.
The verdict
NCT04969861, a Phase 2 study, was terminated before completion, sponsored by Nektar Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, open-label, Phase 2/3 study that will evaluate the efficacy and safety of bempegaldesleukin (BEMPEG; NKTR-214) combined with pembrolizumab compared with pembrolizumab monotherapy in patients with recurrent or metastatic HNSCC with positive PD-L1 expression (CPS ≥ 1).
Interventions
- DRUG Pembrolizumab
- DRUG Bempegaldesleukin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2022-03-09 |
| Est. Completion | 2022-04-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04969861
The ClinicalTrials.gov registry entry for NCT04969861 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nektar Therapeutics, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT04969861 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04969861 about?
NCT04969861 is a clinical study titled "BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)". This is a multicenter, randomized, open-label, Phase 2/3 study that will evaluate the efficacy and safety of bempegaldesleukin (BEMPEG; NKTR-214) combined with pembrolizumab compared with pembrolizumab monotherapy in patients with recurrent or metastatic HNSCC with positive PD-L1 expression (CPS ≥ 1...
What is the current status of trial NCT04969861?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2022-03-09. Estimated completion is 2022-04-22.
What interventions are being tested in trial NCT04969861?
The interventions under investigation include: Pembrolizumab (DRUG), Bempegaldesleukin (DRUG).
Who is sponsoring clinical trial NCT04969861?
This trial is sponsored by Nektar Therapeutics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.